Cindy Motz
Stock Analyst at Goldman Sachs
(0.17)
# 3,275
Out of 4,482 analysts
23
Total ratings
15.38%
Success rate
-18.37%
Average return
Main Sectors:
Top Industries:
8 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLN MultiPlan | Maintains: Neutral | $5.5 → $2.05 | $0.28 | +620.56% | 2 | Nov 16, 2022 | |
| MDRX Veradigm | Upgrades: Buy | $22 → $23 | $9.50 | +142.11% | 2 | Nov 9, 2022 | |
| HQY HealthEquity | Upgrades: Neutral | $64 → $77 | $82.57 | -6.75% | 2 | Oct 21, 2022 | |
| ACCD Accolade | Maintains: Buy | $15 → $16 | $3.61 | +343.21% | 5 | Oct 7, 2022 | |
| SHCR Sharecare | Maintains: Neutral | $1.5 → $2.1 | $1.37 | +53.28% | 3 | Sep 21, 2022 | |
| HCAT Health Catalyst | Maintains: Buy | $29 → $18 | $6.19 | +190.79% | 3 | Aug 10, 2022 | |
| DOCS Doximity | Maintains: Buy | $53 → $46 | $27.50 | +67.27% | 3 | Aug 8, 2022 | |
| TDOC Teladoc Health | Downgrades: Neutral | $55 → $36 | $9.21 | +290.88% | 3 | Jul 28, 2022 |
MultiPlan
Nov 16, 2022
Maintains: Neutral
Price Target: $5.5 → $2.05
Current: $0.28
Upside: +620.56%
Veradigm
Nov 9, 2022
Upgrades: Buy
Price Target: $22 → $23
Current: $9.50
Upside: +142.11%
HealthEquity
Oct 21, 2022
Upgrades: Neutral
Price Target: $64 → $77
Current: $82.57
Upside: -6.75%
Accolade
Oct 7, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $3.61
Upside: +343.21%
Sharecare
Sep 21, 2022
Maintains: Neutral
Price Target: $1.5 → $2.1
Current: $1.37
Upside: +53.28%
Health Catalyst
Aug 10, 2022
Maintains: Buy
Price Target: $29 → $18
Current: $6.19
Upside: +190.79%
Doximity
Aug 8, 2022
Maintains: Buy
Price Target: $53 → $46
Current: $27.50
Upside: +67.27%
Teladoc Health
Jul 28, 2022
Downgrades: Neutral
Price Target: $55 → $36
Current: $9.21
Upside: +290.88%